NO317397B1 - Assay for inhibitorer av DP-1- og DP-proteiner - Google Patents
Assay for inhibitorer av DP-1- og DP-proteiner Download PDFInfo
- Publication number
- NO317397B1 NO317397B1 NO19965584A NO965584A NO317397B1 NO 317397 B1 NO317397 B1 NO 317397B1 NO 19965584 A NO19965584 A NO 19965584A NO 965584 A NO965584 A NO 965584A NO 317397 B1 NO317397 B1 NO 317397B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- assay
- cell
- dna
- binding
- Prior art date
Links
- CPMBELNSUCVCNT-UHFFFAOYSA-N 3-(2,4-dihydroxy-5-propan-2-ylphenyl)-4-[1-(2-piperidin-4-ylethyl)indol-5-yl]-1H-1,2,4-triazol-5-one Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(CCC4CCNCC4)C3=CC=2)=C1O CPMBELNSUCVCNT-UHFFFAOYSA-N 0.000 title claims abstract description 233
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 192
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 183
- 238000003556 assay Methods 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title description 2
- 230000026731 phosphorylation Effects 0.000 claims abstract description 53
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims description 129
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- 239000000284 extract Substances 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 40
- 230000027455 binding Effects 0.000 claims description 38
- 239000000833 heterodimer Substances 0.000 claims description 38
- 238000009739 binding Methods 0.000 claims description 33
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 230000001360 synchronised effect Effects 0.000 claims description 9
- 102100024027 Transcription factor E2F3 Human genes 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 101710138752 Transcription factor E2F3 Proteins 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 230000000865 phosphorylative effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 230000006369 cell cycle progression Effects 0.000 abstract description 25
- 230000001105 regulatory effect Effects 0.000 abstract description 19
- 108020004414 DNA Proteins 0.000 abstract description 12
- 102000004853 Transcription Factor DP1 Human genes 0.000 abstract description 5
- 108090001097 Transcription Factor DP1 Proteins 0.000 abstract description 5
- 102000015699 E2F1 Transcription Factor Human genes 0.000 abstract 1
- 108010063774 E2F1 Transcription Factor Proteins 0.000 abstract 1
- 101710155964 Diuretic hormone 1 Proteins 0.000 description 233
- 101000639778 Drosophila melanogaster RNA polymerase-associated protein Rtf1 Proteins 0.000 description 85
- 101000666370 Homo sapiens Transcription factor Dp-1 Proteins 0.000 description 85
- 102100038130 Transcription factor Dp-1 Human genes 0.000 description 85
- 230000000694 effects Effects 0.000 description 84
- 230000004568 DNA-binding Effects 0.000 description 70
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 64
- 102000004196 processed proteins & peptides Human genes 0.000 description 46
- 229920001184 polypeptide Polymers 0.000 description 39
- 230000022131 cell cycle Effects 0.000 description 34
- 230000003993 interaction Effects 0.000 description 33
- 238000000034 method Methods 0.000 description 28
- 239000000306 component Substances 0.000 description 27
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 17
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 16
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 230000002103 transcriptional effect Effects 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 9
- 101710176384 Peptide 1 Proteins 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 230000018199 S phase Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 108010091748 peptide A Proteins 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000009848 hypophosphorylation Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 208000010370 Adenoviridae Infections Diseases 0.000 description 5
- 206010060931 Adenovirus infection Diseases 0.000 description 5
- 241001135569 Human adenovirus 5 Species 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000012133 immunoprecipitate Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000022983 regulation of cell cycle Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000002554 Cyclin A Human genes 0.000 description 4
- 108010068192 Cyclin A Proteins 0.000 description 4
- 108010093502 E2F Transcription Factors Proteins 0.000 description 4
- 102000001388 E2F Transcription Factors Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000030609 dephosphorylation Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108091008819 oncoproteins Proteins 0.000 description 4
- 102000027450 oncoproteins Human genes 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 241000255601 Drosophila melanogaster Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- -1 pl07 Proteins 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000944683 Bandara Species 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101500026142 Homo sapiens Processed cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 2
- 241000288049 Perdix perdix Species 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102400000755 Processed cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102100023444 Centromere protein K Human genes 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000019274 E2F Family Human genes 0.000 description 1
- 108050006730 E2F Family Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100380508 Homo sapiens ATF2 gene Proteins 0.000 description 1
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710107921 Secreted protein BARF1 Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- UGQQAJOWXNCOPY-VBCJEVMVSA-N i1osj03h46 Chemical compound C([C@H]12)C[C@H]3[C@@](C4(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]4(Cl)[C@H]3CC[C@@H]1[C@]1(Cl)C(Cl)=C(Cl)[C@@]2(Cl)C1(Cl)Cl UGQQAJOWXNCOPY-VBCJEVMVSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920009537 polybutylene succinate adipate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9413327A GB9413327D0 (en) | 1994-07-01 | 1994-07-01 | Assay for inhibitors of dp-1 |
| PCT/GB1995/001567 WO1996001425A2 (en) | 1994-07-01 | 1995-07-03 | Assay for inhibitors of dp-1 and other dp proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965584D0 NO965584D0 (no) | 1996-12-27 |
| NO965584L NO965584L (no) | 1997-02-28 |
| NO317397B1 true NO317397B1 (no) | 2004-10-25 |
Family
ID=10757696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19965584A NO317397B1 (no) | 1994-07-01 | 1996-12-27 | Assay for inhibitorer av DP-1- og DP-proteiner |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5871901A (ja) |
| EP (1) | EP0769144B1 (ja) |
| JP (1) | JPH10502252A (ja) |
| AT (1) | ATE186119T1 (ja) |
| AU (1) | AU698473B2 (ja) |
| CA (1) | CA2193091A1 (ja) |
| DE (2) | DE769144T1 (ja) |
| DK (1) | DK0769144T3 (ja) |
| FI (1) | FI965289A (ja) |
| GB (1) | GB9413327D0 (ja) |
| NO (1) | NO317397B1 (ja) |
| NZ (1) | NZ288712A (ja) |
| WO (1) | WO1996001425A2 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127505A (en) * | 1995-02-02 | 2000-10-03 | Simula Inc. | Impact resistant polyurethane and method of manufacture thereof |
| US6159691A (en) * | 1996-05-15 | 2000-12-12 | Prolifix Limited | Assay for a putative regulator of cell cycle progression |
| GB9610195D0 (en) * | 1996-05-15 | 1996-07-24 | Medical Res Council | Assay |
| US6387649B1 (en) | 1996-09-30 | 2002-05-14 | Prolifix Limited | Assay for a regulator of cell cycle progression |
| CA2267188A1 (en) * | 1996-09-30 | 1998-04-09 | Kyowa Hakko Kogyo Co., Ltd. | E2f activity inhibiting compound |
| AU3478399A (en) * | 1998-04-09 | 1999-11-01 | E.I. Du Pont De Nemours And Company | Cell cycle regulatory proteins cdc-16, dp-1, dp-2 and e2f from plants |
| GB0308711D0 (en) * | 2003-04-15 | 2003-05-21 | Univ The Glasgow | Assay methods |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0905236A1 (en) * | 1992-10-29 | 1999-03-31 | Medical Research Council | Transcription factor DP-1 |
| EP0682704A1 (en) * | 1993-02-12 | 1995-11-22 | The Salk Institute For Biological Studies | Phospho-specific antibodies against transcription factors, more specifically against a creb derived peptide |
-
1994
- 1994-07-01 GB GB9413327A patent/GB9413327D0/en active Pending
-
1995
- 1995-07-03 AU AU28036/95A patent/AU698473B2/en not_active Ceased
- 1995-07-03 US US08/602,846 patent/US5871901A/en not_active Expired - Fee Related
- 1995-07-03 EP EP95923486A patent/EP0769144B1/en not_active Expired - Lifetime
- 1995-07-03 DE DE0769144T patent/DE769144T1/de active Pending
- 1995-07-03 DE DE69513025T patent/DE69513025T2/de not_active Expired - Fee Related
- 1995-07-03 NZ NZ288712A patent/NZ288712A/en not_active IP Right Cessation
- 1995-07-03 DK DK95923486T patent/DK0769144T3/da active
- 1995-07-03 WO PCT/GB1995/001567 patent/WO1996001425A2/en active IP Right Grant
- 1995-07-03 CA CA002193091A patent/CA2193091A1/en not_active Abandoned
- 1995-07-03 JP JP8503745A patent/JPH10502252A/ja active Pending
- 1995-07-03 AT AT95923486T patent/ATE186119T1/de not_active IP Right Cessation
-
1996
- 1996-12-27 NO NO19965584A patent/NO317397B1/no not_active IP Right Cessation
- 1996-12-31 FI FI965289A patent/FI965289A/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE186119T1 (de) | 1999-11-15 |
| EP0769144A2 (en) | 1997-04-23 |
| WO1996001425A2 (en) | 1996-01-18 |
| AU2803695A (en) | 1996-01-25 |
| NO965584D0 (no) | 1996-12-27 |
| DK0769144T3 (da) | 2000-05-08 |
| CA2193091A1 (en) | 1996-01-18 |
| EP0769144B1 (en) | 1999-10-27 |
| NZ288712A (en) | 1998-09-24 |
| DE69513025T2 (de) | 2000-04-13 |
| FI965289A0 (fi) | 1996-12-31 |
| JPH10502252A (ja) | 1998-03-03 |
| DE69513025D1 (de) | 1999-12-02 |
| NO965584L (no) | 1997-02-28 |
| WO1996001425A3 (en) | 1996-03-14 |
| DE769144T1 (de) | 1997-07-10 |
| GB9413327D0 (en) | 1994-08-24 |
| US5871901A (en) | 1999-02-16 |
| FI965289A (fi) | 1996-12-31 |
| AU698473B2 (en) | 1998-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krek et al. | Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase | |
| Chen et al. | A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock | |
| Bandara et al. | DP‐1: a cell cycle‐regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. | |
| Ivey-Hoyle et al. | Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F | |
| Adams et al. | Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors | |
| Welch et al. | A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle | |
| Girling et al. | A new component of the transcription factor DRTF1/E2F | |
| Kanner et al. | Immunoaffinity purification of tyrosine-phosphorylated cellular proteins | |
| US6962792B1 (en) | Methods and means for inhibition of Cdk4 activity | |
| US5863757A (en) | Transcription factor DP-1 | |
| HUT74839A (en) | A novel nuclear mitotic phosphoprotein | |
| JP2006340730A (ja) | 転写因子−ｅ２ｆ−５ | |
| JP2001504681A (ja) | 蛋白質相互作用の阻害 | |
| NO317397B1 (no) | Assay for inhibitorer av DP-1- og DP-proteiner | |
| Dou et al. | Cyclin D1/cdk2 kinase is present in a G1 phase-specific protein complex Yi1 that binds to the mouse thymidine kinase gene promoter | |
| CA2301333C (en) | Prb2/p130 peptide inhibitors of cdk2 kinase activity | |
| AU709319B2 (en) | Transcription factor E2F-4 | |
| Yee et al. | Biochemical characterization of the human cyclin-dependent protein kinase activating kinase: Identification of p35 as a novel regulatory subunit | |
| EP0835319A1 (en) | INTERACTION OF p53 WITH TRANSCRIPTION FACTOR DP-1 | |
| US6303335B1 (en) | Transcription factor E2F-4 | |
| US7160677B1 (en) | Transcription factor DP-1 | |
| CA2603132A1 (en) | Peptide inhibitors of cyclin-dependent kinase activity and uses thereof | |
| Blue et al. | 220 and 130 kDa myosin light chain kinases have distinct tissue distributions and intracellular localization patterns | |
| JP2008515797A (ja) | オスの避妊標的物としてのｔｓｓｋファミリーメンバーおよびｔｓｋｓの評価 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |